176 related articles for article (PubMed ID: 30537114)
1. MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.
Improgo MR; Tesar B; Klitgaard JL; Magori-Cohen R; Yu L; Kasar S; Chaudhary D; Miao W; Fernandes SM; Hoang K; Westlin WF; Kim HT; Brown JR
Br J Haematol; 2019 Mar; 184(6):925-936. PubMed ID: 30537114
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.
Shuai W; Lin P; Strati P; Patel KP; Routbort MJ; Hu S; Wei P; Khoury JD; You MJ; Loghavi S; Tang Z; Fang H; Thakral B; Medeiros LJ; Wang W
Blood Cancer J; 2020 Aug; 10(8):86. PubMed ID: 32848129
[TBL] [Abstract][Full Text] [Related]
3. Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.
Insuasti-Beltran G; Gale JM; Wilson CS; Foucar K; Czuchlewski DR
Arch Pathol Lab Med; 2015 Aug; 139(8):1035-41. PubMed ID: 26230596
[TBL] [Abstract][Full Text] [Related]
4. Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.
Baer C; Dicker F; Kern W; Haferlach T; Haferlach C
Leukemia; 2017 Jun; 31(6):1355-1362. PubMed ID: 27840426
[TBL] [Abstract][Full Text] [Related]
5. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome.
Martínez-Trillos A; Pinyol M; Navarro A; Aymerich M; Jares P; Juan M; Rozman M; Colomer D; Delgado J; Giné E; González-Díaz M; Hernández-Rivas JM; Colado E; Rayón C; Payer AR; Terol MJ; Navarro B; Quesada V; Puente XS; Rozman C; López-Otín C; Campo E; López-Guillermo A; Villamor N
Blood; 2014 Jun; 123(24):3790-6. PubMed ID: 24782504
[TBL] [Abstract][Full Text] [Related]
6. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
[TBL] [Abstract][Full Text] [Related]
8. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
9. Genetic and Clinical Characteristics of Korean Chronic Lymphocytic Leukemia Patients with High Frequencies of
Ahn A; Kim HS; Kim TY; Lee JM; Kang D; Yu H; Lee CY; Kim Y; Eom KS; Kim M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834590
[TBL] [Abstract][Full Text] [Related]
10. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
[TBL] [Abstract][Full Text] [Related]
11. Lack of Associations between TLR9 and MYD88 Gene Polymorphisms and Risk of Chronic Lymphocytic Leukemia.
Ali YB; Foad RM; Abdel-Wahed E
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3245-3250. PubMed ID: 29286214
[TBL] [Abstract][Full Text] [Related]
12. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
13. Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.
Shekhar R; Naseem S; Binota J; Varma N; Malhotra P
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):231-239. PubMed ID: 33217360
[TBL] [Abstract][Full Text] [Related]
14. Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.
Giménez N; Schulz R; Higashi M; Aymerich M; Villamor N; Delgado J; Juan M; López-Guerra M; Campo E; Rosich L; Seiffert M; Colomer D
Leukemia; 2020 Jan; 34(1):100-114. PubMed ID: 31197259
[TBL] [Abstract][Full Text] [Related]
15. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
16. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
[TBL] [Abstract][Full Text] [Related]
17. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Mansouri L; Thorvaldsdottir B; Sutton LA; Karakatsoulis G; Meggendorfer M; Parker H; Nadeu F; Brieghel C; Laidou S; Moia R; Rossi D; Catherwood M; Kotaskova J; Delgado J; Rodríguez-Vicente AE; Benito R; Rigolin GM; Bonfiglio S; Scarfo L; Mattsson M; Davis Z; Gogia A; Rani L; Baliakas P; Foroughi-Asl H; Jylhä C; Skaftason A; Rapado I; Miras F; Martinez-Lopez J; de la Serna J; Rivas JMH; Thornton P; Larráyoz MJ; Calasanz MJ; Fésüs V; Mátrai Z; Bödör C; Smedby KE; Espinet B; Puiggros A; Gupta R; Bullinger L; Bosch F; Tazón-Vega B; Baran-Marszak F; Oscier D; Nguyen-Khac F; Zenz T; Terol MJ; Cuneo A; Hernández-Sánchez M; Pospisilova S; Mills K; Gaidano G; Niemann CU; Campo E; Strefford JC; Ghia P; Stamatopoulos K; Rosenquist R
Leukemia; 2023 Feb; 37(2):339-347. PubMed ID: 36566271
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
[TBL] [Abstract][Full Text] [Related]
19. Aberrant TIRAP and MyD88 expression in B-cell chronic lymphocytic leukemia.
Antosz H; Sajewicz J; Marzec-Kotarska B; Dmoszyńska A; Baszak J; Jargiełło-Baszak M
Blood Cells Mol Dis; 2013 Jun; 51(1):48-55. PubMed ID: 23419703
[TBL] [Abstract][Full Text] [Related]
20. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
Gachard N; Parrens M; Soubeyran I; Petit B; Marfak A; Rizzo D; Devesa M; Delage-Corre M; Coste V; Laforêt MP; de Mascarel A; Merlio JP; Bouabdhalla K; Milpied N; Soubeyran P; Schmitt A; Bordessoule D; Cogné M; Feuillard J
Leukemia; 2013 Jan; 27(1):183-9. PubMed ID: 22944768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]